The company's main focus is on developing an investigational drug called voclosporin for the treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome. Aurinia has a global presence with its head office in Victoria, British Columbia, and a commercial hub in Rockville, Maryland. In January 2021, the company introduced the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis.